Argus Investors Counsel Inc. Has $5.90 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Argus Investors Counsel Inc. grew its position in Eli Lilly and Company (NYSE:LLYFree Report) by 10.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,581 shares of the company’s stock after buying an additional 740 shares during the quarter. Eli Lilly and Company accounts for 3.6% of Argus Investors Counsel Inc.’s holdings, making the stock its 2nd largest holding. Argus Investors Counsel Inc.’s holdings in Eli Lilly and Company were worth $5,898,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Versant Capital Management Inc lifted its position in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after acquiring an additional 13 shares in the last quarter. Moseley Investment Management Inc. lifted its position in Eli Lilly and Company by 0.4% during the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after buying an additional 14 shares in the last quarter. CGN Advisors LLC lifted its position in Eli Lilly and Company by 1.4% during the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after buying an additional 14 shares in the last quarter. Twin Peaks Wealth Advisors LLC lifted its position in Eli Lilly and Company by 2.0% during the first quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock worth $559,000 after buying an additional 14 shares in the last quarter. Finally, Pitti Group Wealth Management LLC lifted its position in Eli Lilly and Company by 0.8% during the first quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company’s stock worth $1,271,000 after buying an additional 14 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Truist Financial lifted their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $769.53.

Get Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Stock Up 0.6 %

NYSE:LLY traded up $5.21 during midday trading on Thursday, reaching $808.12. The company had a trading volume of 3,024,199 shares, compared to its average volume of 3,006,071. The firm has a market capitalization of $768.05 billion, a price-to-earnings ratio of 119.02, a PEG ratio of 1.75 and a beta of 0.37. The stock’s fifty day simple moving average is $764.43 and its 200-day simple moving average is $690.85. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $820.60. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. During the same period last year, the business posted $1.62 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.78 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.